

Lysine¹¹-Linked Polyubiquitination of the AnkB F-Box Effector of *Legionella pneumophila*

William M. Bruckert,^a Yousef Abu Kwaik^{a,b}

Department of Microbiology and Immunology^a and Center for Predictive Medicine,^b University of Louisville College of Medicine, Louisville, Kentucky, USA

The fate of the polyubiquitinated protein is determined by the lysine linkages involved in the polymerization of the ubiquitin monomers, which has seven lysine residues (K⁶, K¹¹, K²⁷, K²⁹, K³³, K⁴⁸, and K⁶³). The translocated AnkB effector of the intravacuolar pathogen *Legionella pneumophila* is a bona fide F-box protein, which is localized to the cytosolic side of the *Legionella*-containing vacuole (LCV) and is essential for intravacuolar proliferation within macrophages and amoebae. The F-box domain of AnkB interacts with the host SCF1 E3 ubiquitin ligase that triggers the decoration of the LCV with K⁴⁸-linked polyubiquitinated proteins that are targeted for proteasomal degradation. Here we report that AnkB becomes rapidly polyubiquitinated within the host cell, and this modification is independent of the F-box domain of AnkB, indicating host-mediated polyubiquitination. We show that the AnkB effector interacts specifically with the host E3 ubiquitin ligase Trim21. Mass spectrometry analyses have shown that AnkB is modified by K¹¹-linked polyubiquitination, which has no effect on its stability. This work shows the first example of K¹¹-linked polyubiquitination of a bacterial effector and its interaction with the host Trim21 ubiquitin ligase.

Legionella pneumophila, the causative agent of Legionnaires' disease, infects a wide array of protozoan hosts in the aquatic environment (1–4). Following inhalation of aerosols containing *L. pneumophila*, the bacteria replicate within alveolar macrophages, after remodeling their phagosome into a rough endoplasmic reticulum-derived vacuole termed the *Legionella*-containing vacuole (LCV) (5, 6). Mechanisms of LCV biogenesis are unknown, but they are dependent on the type IV Dot/Icm secretion system (7, 8). The ~300 translocated effector proteins injected by the Dot/Icm system into the host cell manipulate a myriad of host cellular processes, which enable intracellular proliferation in evolutionarily distant hosts (5, 6, 9). Bioinformatic analyses have revealed that many of the *L. pneumophila* translocated effector proteins share a resemblance to eukaryotic proteins, which is thought to have occurred through horizontal gene transfer and adaptation to the host (10–12).

Unlike most Dot/Icm-translocated effectors, the eukaryote-like F-box effector protein AnkB is required for intracellular proliferation in human macrophages and amoebae in the AA100/130b strain and the Paris strain but not in the strain Philadelphia-derived Lp02 strain (13–15). Following its translocation, AnkB is anchored to the cytosolic face of the LCV membrane through host-mediated farnesylation (16), where it triggers polyubiquitination of the LCV (14, 17). The F-box domain of AnkB interacts directly with the SCF1 (SKP1/CUL1/F-box) E3 ubiquitin ligase complex, which is acquired by the LCV (18). The interaction with the SCF1 complex results in AnkB-mediated decoration of the LCV with lysine⁴⁸-linked polyubiquitinated proteins, which are subjected to host-mediated proteasomal degradation (19). This results in a robust rise in the levels of free cellular amino acids above the threshold needed as the main sources of carbon and energy for intravacuolar replication of *L. pneumophila* (19–21).

Ubiquitin is a highly conserved, eukaryotic, 76-amino-acid protein that can be covalently linked to a lysine residue in a substrate protein, resulting in ubiquitination of the protein. The process of ubiquitination begins with an E1 ubiquitin activation enzyme (22), followed by an E2 ubiquitin-conjugating enzyme (23). This process is completed by an E3 ubiquitin ligase that transfers

ubiquitin from E2 to a lysine residue of the substrate protein (24). The substrate protein can be monoubiquitinated, or ubiquitin can be polymerized through any of the 7 lysine residues (K⁶, K¹¹, K²⁷, K²⁹, K³³, K⁴⁸, and K⁶³) of ubiquitin to form a polyubiquitin chain on the substrate protein (25, 26). The fate of the polyubiquitinated protein depends on the lysine residue within ubiquitin in the polyubiquitin chain (25, 26). The most studied polyubiquitin chains are the K⁴⁸-linked chains, which result in proteasomal degradation of the substrate protein, while K⁶³-linked polyubiquitin chains are involved in nondegradation processes such as alteration of protein function or subcellular location (27, 28). The fate of polyubiquitination through K⁶, K¹¹, K²⁷, K²⁹, and K³³ linkages is not well defined. However, it has been shown that some of these modes of polyubiquitination may lead to proteasomal degradation (29), cell cycle regulation (30), DNA repair, cellular signaling, and regulation (31, 32). The tumor suppressor Beclin 1 undergoes proteasomal degradation through K¹¹-linked polyubiquitination (33). The majority of the knowledge on K¹¹-linked polyubiquitination has come from the anaphase-promoting complex (APC/C) E3 ubiquitin ligase (34, 35). APC/C promotes proteasomal degradation of substrates through K¹¹-linked polyubiquitin chains, which play a major role in cell cycle regulation (36, 37). Interestingly, major histocompatibility complex class I (MHC-I) is polyubiquitinated through a mixture of K¹¹- and K⁶³-linked polyubiquitin chains to undergo receptor internalization (38).

Received 11 September 2015 Returned for modification 6 October 2015

Accepted 10 October 2015

Accepted manuscript posted online 19 October 2015

Citation Bruckert WM, Abu Kwaik Y. 2016. Lysine¹¹-linked polyubiquitination of the AnkB F-box effector of *Legionella pneumophila*. Infect Immun 84:99–107. doi:10.1128/IAI.01165-15.

Editor: A. J. Bäuml

Address correspondence to Yousef Abu Kwaik, abukwaik@louisville.edu.

Supplemental material for this article may be found at <http://dx.doi.org/10.1128/IAI.01165-15>.

Copyright © 2015, American Society for Microbiology. All Rights Reserved.

It is becoming increasingly apparent that bacterial pathogens manipulate eukaryotic cellular ubiquitination machinery for various purposes, and many translocated bacterial effectors become polyubiquitinated by the host cell machinery (19, 39). The *Salmonella enterica* SopA effector is ubiquitinated by HsRMA1, which results in its proteasomal degradation (40, 41), while the SopB effector is ubiquitinated by TRAF6 through K⁶³-linked polyubiquitination, which alters subcellular localization (42, 43). The SopE and SptP effectors of *Salmonella* are ubiquitinated following translocation and are degraded by the proteasome (44). Ubiquitination of the *L. pneumophila* effector SidH leads to its degradation (45, 46). Interestingly, the *Pseudomonas aeruginosa* A2 phospholipase ExoU has been shown to be modified by a diubiquitin chain, which could result in altered trafficking (47). In addition to diubiquitination, the enzymatic functions of ExoU have been shown to be activated by interactions with ubiquitin following translocation, indicating another role for ubiquitin modification of bacterial proteins (48). These few examples highlight various established polyubiquitinations of bacterial effectors. To date, there has been no example of any bacterial effector protein polyubiquitination through K⁶, K¹¹, K²⁷, K²⁹, or K³³ linkages.

The Trim21 E3 ubiquitin ligase plays a major role in the regulation of the innate immune response by ubiquitinating interferon regulatory factor 3 (IRF3), IRF5, IRF7, and IRF8 (49–53). Trim21 interacts with the F-box protein Skp2 as well as the Cul1 component of the SCF1 E3 ubiquitin ligase complex to promote ubiquitination of p27 (54). While most Trim21 substrates are degraded by the proteasome, certain substrates have been shown to be monoubiquitinated (55). Polyubiquitination of IRF8 with unknown lysine linkages by Trim21 does not lead to its degradation (56). Trim21 also promotes signaling of immune pathways through K⁶³-linked polyubiquitinated chains (57). In addition, Trim21 has been shown to catalyze K⁴⁸-linked as well as K⁶³-linked polyubiquitination. However, Trim21 has not been shown to synthesize K¹¹-linked polyubiquitinated chains.

Here we report polyubiquitination of the *L. pneumophila* translocated F-box effector AnkB through K¹¹-linked polyubiquitination, which does not affect its half-life. We show that the E3 ubiquitin ligase Trim21 is a specific binding partner for AnkB.

MATERIALS AND METHODS

Cell cultures and bacterial strains. *Escherichia coli* strain DH5 α was used for cloning and plasmid preparation purposes. HEK293T cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) (BioWest) and 200 mM L-glutamine (Corning) at 37°C in a 5% CO₂ atmosphere.

Transfection of HEK293T cells. The *ankB* gene was cloned into the mammalian expression vector p3XFlag-CMV-10. Generation of 3 \times Flag-tagged AnkB substitution mutant AnkB^{9L10P}, 3 \times Flag-tagged AnkB Δ F-box, and 3 \times Flag-tagged AnkH was described previously (17, 58). Hemagglutinin (HA)-tagged Trim21 was a kind gift from Yong-Jun Liu at the University of Baylor. HEK293T cells were grown to ~70% confluence and plated onto poly-L-lysine-treated 6-well plates. Following 24 h of incubation, HEK293T cell monolayers were transfected with ~2 μ g plasmid DNA/well by using polyethylenimine (Polysciences) for 24 h.

In vivo coimmunoprecipitation. HEK293T cells were transfected with 3 \times Flag-tagged AnkB, AnkB^{9L10P}, AnkB Δ F-box, AnkH, and HA-tagged Trim21 for 24 h and collected in lysis buffer containing 50 mM Tris (pH 7.4), 0.25 M NaCl, 0.5% Triton X-100, 1 mM EDTA, 50 mM NaF, 0.1 mM Na₃VO₄, and EDTA-free protease inhibitor cocktail (Roche). Flag-tagged and HA-tagged proteins were immunoprecipitated by using anti-

Flag M2 agarose (Sigma) or anti-HA affinity gel (Sigma) according to the manufacturer's instructions.

Antibodies and Western blot analysis. Immunoprecipitated proteins were heated at 99°C for 5 min in sample buffer, separated by 10.4 to 15% SDS-PAGE, and transferred onto a polyvinylidene difluoride (PVDF) membrane. Anti-Flag (Sigma) used at a 1:1,000 dilution, antiactin (Proteintech) used at 1:15,000, antiubiquitin (Cell Signaling) used at 1:1,000, anti-lysine 48 ubiquitin (Cell Signaling) used at 1:1,000, and anti-lysine 63 ubiquitin (Cell Signaling) used at 1:1,000 were incubated overnight in 5% milk at 4°C. Anti-HA (Cell Signaling) was used at 1:1,000 and incubated in 5% bovine serum albumin (BSA) overnight at 4°C.

Cycloheximide inhibition. HEK293T cells plated in 6-well plates were transfected with 3 \times Flag-AnkB for 24 h. The proteasomal inhibitor MG132 (Selleckchem) used at 20 μ M was added to the indicated cells 2 h prior to cycloheximide treatment at 100 μ g/ml. At the indicated time points, cells were lysed and subjected to SDS-PAGE and immunoblotting with anti-Flag and antiactin antibodies.

Nano-LC-MS2 data collection. In collaboration with Steve Gygi, Ryan Kunz, and Ross Tomaino at the Harvard University Taplin Mass Spectrometry Facility, mass spectrometry (MS) data were collected on an Orbitrap Fusion mass spectrometer equipped with an Easy Nano-LC 1000 instrument for sample handling and liquid chromatography (LC). Peptides were separated on a 75- μ m by 30-cm hand-pulled fused silica microcapillary column with a needle tip diameter of <10 μ m and packed with 1.8- μ m 120-Å GP-C₁₈ beads (Sepax Technologies Inc.). The column was equilibrated with buffer A (3% ACN plus 0.125% FA). Peptides were loaded onto the column with 100% buffer A. Separation and elution from the column were achieved by using a 90-min 3 to 25% gradient of buffer B (100% ACN plus 0.125% FA). Survey scans of peptide precursors from *m/z* 400 to 1,400 were performed at 120K resolution (at *m/z* 200), with AGC of 50k, a maximum injection time of 100 ms, monoisotopic precursor selection turned on, charge state of 2 to 6, and dynamic exclusion for 45 s with a 10-ppm tolerance. Tandem MS (MS/MS) was performed in top-speed mode (2-s cycles) starting with the most intense precursor having an intensity of >5k. Parent ions were isolated in the quadrupole (*m/z* 0.7 isolation window). Collision-induced dissociation was performed in the ion trap with a rapid scan rate, 35% collision energy, AGC of 10k, maximum injection time of 35 ms, and the parallelizable time turned on.

Mass spectrometry data analysis. A suite of in-house software tools was used for .RAW file processing, controlling peptide and protein false discovery rates, and assembling peptide-level data into protein-level data (59). MS/MS spectra were searched by using the SEQUEST algorithm (60) against a composite protein database consisting of all protein sequences from the UniProt human database along with common contaminating proteins in both the forward and reverse directions. SEQUEST parameters used to search the MS data were a precursor tolerance of 50 ppm, a fragment ion tolerance of 1 Da, fully tryptic cleavage, 2 missed cleavages, variable modifications of oxidized methionine (15.9949 Da), alkylation of cysteine (57.0214 Da), and a diglycine motif on lysine (114.0429 Da). A target-decoy strategy was used to determine false discovery rates (61). The peptide-level false discovery rate was restricted to <1% by using linear discriminate analysis based on several different SEQUEST parameters, including an Xcorr of \geq 1.0, deltaXcorr, charge state, and a minimum peptide length of 7 amino acids (59). An algorithm similar to Ascore was used for diglycine localization and site quantification (62).

RESULTS

Ubiquitination of the *L. pneumophila* translocated effector AnkB. To determine whether the AnkB effector of *L. pneumophila* strain AA100/130b undergoes any posttranslational modifications within eukaryotic cells, we immunoprecipitated ectopically expressed Flag-tagged AnkB and analyzed it by Western blotting with anti-Flag antibodies. In addition to the native AnkB band at ~23 kDa, there were 2 distinct bands at ~37 kDa and ~75 kDa as well as a smear of high-molecular-mass proteins recognized by




FIG 1 Ubiquitination of ectopically expressed AnkB. (A) HEK293T cells were transfected with Flag-tagged AnkB from *L. pneumophila* strain AA100/130b. Cell lysates were immunopurified with anti-Flag agarose and analyzed by immunoblotting with anti-Flag and antiubiquitin antibodies. (B) HEK293T cells were transfected with Flag-tagged AnkB from *L. pneumophila* strain Paris. Cell lysates were purified with anti-Flag agarose and analyzed by immunoblotting with anti-Flag and antiubiquitin antibodies. (C) HEK293T cells were transfected with AnkB variants, Flag-tagged AnkB^{9L10P} or Flag-tagged AnkBΔF-box. Cell lysates were purified with anti-Flag agarose and analyzed by immunoblotting with anti-Flag antibodies.

anti-Flag antibodies (Fig. 1A), which suggested that the distinct bands at ~37 kDa and ~75 kDa may correspond to the potential addition of 2 and 6 ubiquitin monomers to AnkB (Fig. 1A). Reprobing this blot with antiubiquitin antibodies showed that the higher-molecular-mass species were AnkB modified by ubiquitin (Fig. 1A).

To ensure that ubiquitination of AnkB was not limited to *L. pneumophila* strain AA100/130b only, we utilized AnkB of the *L. pneumophila* Paris strain (14), which lacks the C-terminal CaaX motif (16). We performed immunoprecipitation (IP) of Flag-tagged AnkB of strain Paris and immunoblotted the immunoprecipitate with anti-Flag antibodies. Similar to AA100/130b-derived AnkB, the Paris strain AnkB protein showed distinct bands and a high-molecular-mass smear that were determined to be ubiquitinated AnkB (Fig. 1B). We tried to determine whether AnkB is also ubiquitinated during infection. The two major limitations of this approach are that AnkB is poorly expressed during infection and is present only on the LCV membrane, and only ~20% of the cells become infected. We utilized up to 5×10^8 infected cells, but the amount of AnkB detected from the whole sample was very minimal after IP.

AnkB is a bona fide F-box protein (14, 17), and its F-box domain interacts directly with the SKP1 component of the host SCF1 E3 ubiquitin ligase complex on the LCV (14, 17). To determine if the F-box domain of AnkB was required for its ubiquitination, we transfected HEK293T cells with an AnkB variant lacking the F-box domain (AnkBΔF-box) and immunoprecipitated the protein. Western blot analysis showed that deletion of the F-box domain of AnkB did not have an impact on its ubiquitination, as evident from the banding pattern of higher-molecular-mass species of AnkB (Fig. 1C). To ensure that deletion of the F-box domain did not have an impact on the structure of AnkB, we utilized an AnkB substitution mutant (AnkB^{9L10P}/AA) within the F-box domain that does not bind to SKP1. Following immunoprecipitation of AnkB^{9L10P}/AA, the Western blot showed that AnkB^{9L10P}/AA was ubiquitinated similarly to native AnkB, as evident from the banding pattern of higher-molecular-mass species of AnkB (Fig. 1C). Taken together, these results indicate that AnkB is ubiquitinated

and that its ubiquitination is independent of the interaction of its F-box domain with the host SCF1 E3 ubiquitin ligase complex.

AnkB interacts with the E3 ubiquitin ligase Trim21. The ubiquitination of the AnkB variant lacking the F-box domain as well as the AnkB^{9L10P}/AA substitution variant allowed us to exclude a role for the SCF1 E3 ubiquitin ligase in AnkB ubiquitination. Therefore, we sought to determine the E3 ubiquitin ligase that interacts with AnkB. We immunoprecipitated Flag-tagged AnkB from HEK293T cells and performed MS analysis on the proteins that coimmunoprecipitated with AnkB. Our mass spectrometry data showed that the RING finger protein Ro52 (Trim21) copurified with AnkB at a 1:2 ratio. To confirm that AnkB directly interacts with Trim21, we cotransfected HEK293T cells with Flag-tagged AnkB and HA-tagged Trim21. Following cell lysis, Flag-tagged AnkB was coimmunoprecipitated with anti-Flag antibody, and the immunoprecipitate was immunoblotted with anti-HA tag antibody. The data showed a band corresponding to the molecular mass of Trim21 that coimmunoprecipitated with AnkB (Fig. 2A). When the coimmunoprecipitation was reversed through immunoprecipitation with anti-HA antibody and the immunoprecipitate was immunoblotted with anti-Flag antibodies, a band with a molecular mass corresponding to AnkB was detected (Fig. 2B). To determine if the Trim21-AnkB interaction was specific for AnkB, we utilized the *L. pneumophila* translocated effector protein AnkH (58) as a control in the coimmunoprecipi-




FIG 2 AnkB directly interacts with the E3 ubiquitin ligase Trim21. (A) Flag-tagged AnkB or Flag-tagged AnkH was cotransfected with HA-tagged Trim21 in HEK293T cells. Flag-tagged AnkB or Flag-tagged AnkH was coimmunoprecipitated with anti-Flag agarose and subsequently immunoblotted with anti-HA antibodies and anti-Flag antibodies. (B) HA-tagged Trim21 was coimmunoprecipitated by using anti-HA agarose and subsequently immunoblotted with anti-Flag antibodies and anti-HA antibodies.




FIG 3 Ubiquitinated AnkB is not degraded by the proteasome. (A) HEK293T cells were untreated or treated with MG132 for 3 h. Cells were lysed, and the resulting immunoblot was probed with antiubiquitin and antiactin antibodies. (B) HEK293T cells transfected with Flag-tagged AnkB were treated with the protein synthesis inhibitor cycloheximide. To inhibit proteasomal degradation, a subset of cells was pretreated for 2 h with MG132 prior to cycloheximide treatment. At the indicated time points, cells were lysed, and equivalent amounts of protein were subjected to immunoblotting with anti-Flag and antiactin antibodies.

tation. Flag-tagged AnkH was coimmunoprecipitated with anti-Flag antibodies, and the resulting immunoprecipitate was immunoblotted with anti-HA antibodies. Unlike AnkB, Trim21 did not coimmunoprecipitate with AnkH (Fig. 2A). This was confirmed by reversing the coimmunoprecipitation and Western blotting, which also showed a lack of an interaction of Trim21 with the AnkH control (Fig. 2B). Taken together, these results indicate that AnkB specifically interacts with the E3 ubiquitin ligase Trim21. This is the first example of an interaction of a bacterial effector with the host Trim21 ubiquitin ligase.

Ubiquitinated AnkB is not degraded by the proteasome. When proteins are polyubiquitinated through K⁴⁸-linked polymerization of ubiquitin, they are degraded by the proteasome (25). In general, ectopically overexpressed proteins in eukaryotic cells are modified by K⁴⁸-linked polyubiquitination to degrade the overexpressed protein. To determine whether ubiquitination of AnkB led to its proteasomal degradation, we utilized the proteasomal inhibitor MG132 and determined the stability of AnkB in the presence or absence of the protein synthesis inhibitor cycloheximide. To ensure that the MG132 proteasome inhibitor blocked proteasomal degradation, treated or untreated cells were lysed, and a Western blot of the total cell lysate was probed with antiubiquitin and reprobed with antiactin antibodies (Fig. 3A). As expected, cells treated with MG132 had a large increase in the amount of ubiquitinated proteins compared to untreated cells (Fig. 3A). In contrast, our data showed that upon proteasomal inhibition, ubiquitinated AnkB was stable over the 3-h experiment (Fig. 3B). Upon proteasomal inhibition by MG132, the

amounts of unmodified AnkB decreased slightly over time, as some of it was modified and shifted to a higher molecular mass. At 20 to 30 min, the ubiquitination of AnkB became more prominent, as the higher-molecular-mass modified species of AnkB bands exhibited higher intensity than that at 10 min. Therefore, ubiquitination of AnkB does not result in its proteasomal degradation (Fig. 3B).

Polyubiquitin linkages of polyubiquitinated AnkB. Ubiquitin contains 7 lysine residues, all of which can be utilized to polymerize ubiquitin on the substrate protein (25). K⁴⁸-linked polyubiquitination and K⁶³-linked polyubiquitination are the most common and most studied modes of polyubiquitination. We sought to determine the chain linkage of the ubiquitin polymers of ubiquitinated AnkB by mass spectrometry. Depending on the lysine residue within ubiquitin that contains the ubiquitin-ubiquitin linkage, a characteristic mass shift increase of 114 Da (diglycine) is observed by mass spectrometry (63). Flag-tagged AnkB was ectopically expressed in HEK293T cells and immunoprecipitated by using anti-Flag antibody. Immunoprecipitated proteins were resolved by SDS-PAGE and visualized by Coomassie blue staining (Fig. 4A). Of the several bands corresponding to AnkB with a different number of ubiquitin moieties, the most prominent band at ~75 kDa (AnkB plus 6 ubiquitin moieties) was analyzed by mass spectrometry to determine the modified lysine residues within AnkB and ubiquitin. The resulting spectra showed ubiquitination of AnkB on K⁶⁷ in the peptide (residues 63 to 75) (Fig. 4B). More than 90% of the b and y ions with +1, +2, and +3 charges were detected, which provided clear evidence for the ubiq-




FIG 4 AnkB is ubiquitinated on lysine 67. (A) Flag-tagged AnkB was immunoprecipitated from transfected HEK293T cells and analyzed by SDS-PAGE and Coomassie blue staining. (B) The band at ~74 kDa (AnkB plus 6 ubiquitin [Ub] moieties) was analyzed by mass spectrometry, and the resulting spectra within the ubiquitinated AnkB peptide (residues 63 to 75) are shown with the b ions (blue lines) and y ions (red lines). The y ions with a +2 charge are shown with the mass/charge ratio calculated to show ubiquitination on lysine 67 of AnkB.




FIG 5 AnkB is polyubiquitinated through lysine¹¹ of ubiquitin. (A) The ~74-kDa ubiquitinated AnkB band was analyzed by mass spectrometry for ubiquitination of ubiquitin. The resulting spectrum of the modified ubiquitin peptide (residues 7 to 27) is shown, along with the b ions (blue lines) and y ions (red lines) detected. The b ions with a +1 charge and y ions with a +2 charge are shown with the mass/charge ratio calculated to show ubiquitination on lysine¹¹ of ubiquitin. (B) Predicted fragmentation pattern and mass-to-charge ratios of the +1 and +2 charges of the ions within the spectra.

ubiquitination of AnkB on K⁶⁷ (see Fig. S1 in the supplemental material). Within the same ~75-kDa band, ubiquitin was ubiquitinated on K¹¹ in the peptide (residues 7 to 27) (Fig. 5A). The b ions with a +1 charge and the y ions with a +2 charge surrounding the modified lysine residue of ubiquitin are shown, and the calculation provided direct evidence for ubiquitination of ubiquitin on K¹¹ (Fig. 5A and B). Although phosphorylation of proteins has been shown to be a signal for protein ubiquitination (64), we did not detect phosphorylated AnkB in the MS analysis.

To determine the role of host cell ubiquitination of AnkB in its function, we generated a substitution mutant of the ubiquitinated K residue in AnkB (AnkB-K⁶⁷R) and determined whether this abolished the ubiquitination of AnkB. However, following immunoprecipitation from HEK293T cells, the results showed that AnkB ubiquitination was identical to that of native AnkB (Fig. 1). This is not surprising, since in many eukaryotic proteins and the SopB effector of *Salmonella*, ubiquitination can shift from one K residue to another after substitution of the modified residue within a protein (42, 65). Taken together, AnkB is ubiquitinated on K⁶⁷ through K¹¹-linked polyubiquitination, but the lysine residue involved does not have to be the K⁶⁷ residue.

DISCUSSION

Pathogenic bacteria have evolved elaborate mechanisms to counteract and manipulate eukaryotic ubiquitination machinery to subvert the immune response, acquire nutrients through proteasomal degradation, and alter the subcellular localization of effector proteins (39). In this report, we highlight novel K¹¹-linked polyubiquitination of the *L. pneumophila* F-box effector protein AnkB. Our data obtained by IP as well as by MS analyses of the ubiquitinated species show that they are all AnkB species modified by ubiquitin (Fig. 4A), and no other proteins were detected. This is the first example of a bacterial effector undergoing K¹¹-linked polyubiquitination. In all but one of the reported examples of K¹¹-linked polyubiquitination, the substrate protein is degraded by the proteasome (36, 38, 66). Our data showed that K¹¹-linked polyubiquitinated AnkB is not degraded by the proteasome. This suggests that K¹¹-linked polyubiquitination of AnkB could play a unique role in the fate or function of AnkB in addition to the established role of K¹¹-linked polyubiquitination as a proteasomal degradation signal.

Previous reports have shown that F-box proteins undergo autoubiquitination, acting as regulatory mechanisms in most cases (67, 68). However, ubiquitination of AnkB is independent of its F-box domain that interacts with the SCF1 ubiquitin ligase. This raises the question of whether other F-box proteins are ubiquitinated in a manner that does not lead to proteasomal degradation. The ubiquitination of F-box proteins has probably been overlooked due to the fact that F-box proteins cause ubiquitination of their substrates. Perhaps, the ubiquitination of F-box proteins may impact their interaction with specific substrates. The ubiquitination of F-box proteins could alter their subcellular localization, which could allow their interaction with specific substrates localized to vesicles or the plasma membrane. When the ubiquitinated lysine residue in AnkB was replaced with arginine, ubiquitination of AnkB was not affected. This switching of the modified lysine residue upon its substitution is a common process that has been repeatedly observed in other F-box proteins and has been also shown for SopB of *Salmonella* (42, 65). Since there are a total of 19 lysine residues within AnkB, we chose not to replace all of

them, since this would most likely impact the structure and function of the protein independent of the effect of the lack of ubiquitination.

Trim21 has been shown to play a major role in the proteasomal degradation of opsonized intracellular viral particles and is required to prevent certain fatal viral infections (69, 70). Recently, it was shown that Trim21 is recruited to opsonized *Salmonella enterica*, which stimulates NF- κ B activation, but whether it interacts with a bacterial effector or ubiquitinate proteins on the *Salmonella*-containing vacuole is not known (57). While we propose the recognition of a bacterial effector protein for ubiquitination by Trim21, this could imply an additional mechanism similar to the ubiquitination of viral particles. Due to effector proteins being exposed to eukaryotic cytosolic enzymes during bacterial infection, Trim21 would have access to bind and ubiquitinate them. The Trim21-AnkB interaction is the first example of a Trim21 interaction with a bacterial effector. However, whether the Trim21-AnkB interaction is exhibited on the LCV membrane and whether Trim21 is the only enzyme capable of modifying AnkB are still to be determined.

While translocated bacterial proteins have been shown to be ubiquitinated, primarily for proteasomal degradation, K¹¹-linked polyubiquitination of AnkB does not affect its stability. To date, K¹¹-linked polyubiquitination has been observed only on eukaryotic proteins and has been primarily implicated in proteasomal degradation associated with cell cycle regulation. However, RIPA is modified through K¹¹-linked chains in a manner thought to be involved in tumor necrosis factor (TNF) signaling (66). With the few proteins experimentally shown to be modified through K¹¹-linked polyubiquitination, the possible outcomes of this emerging mode of polyubiquitination remain to be defined. It is possible that K¹¹-linked polyubiquitination of AnkB alters its subcellular localization or affects its interaction with substrates that bind the region of AnkB where ubiquitination is exhibited. Future studies will decipher the biological significance of this unique mode of polyubiquitination of the F-box protein.

ACKNOWLEDGMENTS

We gratefully acknowledge Steve Gygi, Ryan Kunz, and Ross Tomaino at the Harvard University Taplin Mass Spectrometry Facility for their proteomic analyses and for their helpful discussion. We thank all members of the Abu Kwaik laboratory for reading of the manuscript and insightful discussion.

Y.A.K. is supported by Public Health Service award 1R01AI120244 from the NIAID and by the commonwealth of Kentucky Research Challenge Trust Fund.

FUNDING INFORMATION

HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) provided funding to Yousef Abu Kwaik under grant number 1R01AI120244.

REFERENCES

1. Molmeret M, Horn M, Wagner M, Santic M, Abu Kwaik Y. 2005. Amoebae as training grounds for intracellular bacterial pathogens. *Appl Environ Microbiol* 71:20–28. <http://dx.doi.org/10.1128/AEM.71.1.20-28.2005>.
2. Price CT, Richards AM, Von Dwingelo JE, Samara HA, Abu Kwaik Y. 2014. Amoeba host-*Legionella* synchronization of amino acid auxotrophy and its role in bacterial adaptation and pathogenic evolution. *Environ Microbiol* 16:350–358. <http://dx.doi.org/10.1111/1462-2920.12290>.
3. Richards AM, Von Dwingelo JE, Price CT, Abu Kwaik Y. 2013. Cellular

- microbiology and molecular ecology of *Legionella*-amoeba interaction. *Virulence* 4:307–314. <http://dx.doi.org/10.4161/viru.24290>.
4. Al-Quadan T, Price CT, Abu Kwaik Y. 2012. Exploitation of evolutionarily conserved amoeba and mammalian processes by *Legionella*. *Trends Microbiol* 20:299–306. <http://dx.doi.org/10.1016/j.tim.2012.03.005>.
 5. Isberg RR, O'Connor TJ, Heidtman M. 2009. The *Legionella* pneumophila replication vacuole: making a cosy niche inside host cells. *Nat Rev Microbiol* 7:13–24. <http://dx.doi.org/10.1038/nrmicro1967>.
 6. Shin S, Roy CR. 2008. Host cell processes that influence the intracellular survival of *Legionella* pneumophila. *Cell Microbiol* 10:1209–1220. <http://dx.doi.org/10.1111/j.1462-5822.2008.01145.x>.
 7. Segal G, Purcell M, Shuman HA. 1998. Host cell killing and bacterial conjugation require overlapping sets of genes within a 22-kb region of the *Legionella* pneumophila genome. *Proc Natl Acad Sci U S A* 95:1669–1674. <http://dx.doi.org/10.1073/pnas.95.4.1669>.
 8. Vogel JP, Andrews HL, Wong SK, Isberg RR. 1998. Conjugative transfer by the virulence system of *Legionella* pneumophila. *Science* 279:873–876. <http://dx.doi.org/10.1126/science.279.5352.873>.
 9. Zhu W, Banga S, Tan Y, Zheng C, Stephenson R, Gately J, Luo ZQ. 2011. Comprehensive identification of protein substrates of the Dot/Icm type IV transporter of *Legionella* pneumophila. *PLoS One* 6:e17638. <http://dx.doi.org/10.1371/journal.pone.0017638>.
 10. Habyarimana F, Al-Khodori S, Kalia A, Graham JE, Price CT, Garcia MT, Kwaik YA. 2008. Role for the ankyrin eukaryotic-like genes of *Legionella* pneumophila in parasitism of protozoan hosts and human macrophages. *Environ Microbiol* 10:1460–1474. <http://dx.doi.org/10.1111/j.1462-2920.2007.01560.x>.
 11. de Felipe KS, Pampou S, Jovanovic OS, Pericone CD, Ye SF, Kalachikov S, Shuman HA. 2005. Evidence for acquisition of *Legionella* type IV secretion substrates via interdomain horizontal gene transfer. *J Bacteriol* 187:7716–7726. <http://dx.doi.org/10.1128/JB.187.22.7716-7726.2005>.
 12. Al-Khodori S, Price CT, Kalia A, Abu Kwaik Y. 2010. Functional diversity of ankyrin repeats in microbial proteins. *Trends Microbiol* 18:132–139. <http://dx.doi.org/10.1016/j.tim.2009.11.004>.
 13. Al-Khodori S, Price CT, Habyarimana F, Kalia A, Abu Kwaik Y. 2008. A Dot/Icm-translocated ankyrin protein of *Legionella* pneumophila is required for intracellular proliferation within human macrophages and protozoa. *Mol Microbiol* 70:908–923. <http://dx.doi.org/10.1111/j.1365-2958.2008.06453.x>.
 14. Lomma M, Dervins-Ravault D, Rolando M, Nora T, Newton HJ, Sansom FM, Sahr T, Gomez-Valero L, Jules M, Hartland EL, Buchrieser C. 2010. The *Legionella* pneumophila F-box protein Lpp2082 (AnkB) modulates ubiquitination of the host protein parvin B and promotes intracellular replication. *Cell Microbiol* 12:1272–1291. <http://dx.doi.org/10.1111/j.1462-5822.2010.01467.x>.
 15. Ensminger AW, Isberg RR. 2010. E3 ubiquitin ligase activity and targeting of BAT3 by multiple *Legionella* pneumophila translocated substrates. *Infect Immun* 78:3905–3919. <http://dx.doi.org/10.1128/IAI.00344-10>.
 16. Price CT, Al-Quadan T, Santic M, Jones SC, Abu Kwaik Y. 2010. Exploitation of conserved eukaryotic host cell farnesylation machinery by an F-box effector of *Legionella* pneumophila. *J Exp Med* 207:1713–1726. <http://dx.doi.org/10.1084/jem.20100771>.
 17. Price CT, Al-Khodori S, Al-Quadan T, Santic M, Habyarimana F, Kalia A, Kwaik YA. 2009. Molecular mimicry by an F-box effector of *Legionella* pneumophila hijacks a conserved polyubiquitination machinery within macrophages and protozoa. *PLoS Pathog* 5:e1000704. <http://dx.doi.org/10.1371/journal.ppat.1000704>.
 18. Bruckert WM, Price CT, Abu Kwaik Y. 2014. Rapid nutritional remodeling of the host cell upon attachment of *Legionella* pneumophila. *Infect Immun* 82:72–82. <http://dx.doi.org/10.1128/IAI.01079-13>.
 19. Price CT, Al-Quadan T, Santic M, Rosenshine I, Abu Kwaik Y. 2011. Host proteasomal degradation generates amino acids essential for intracellular bacterial growth. *Science* 334:1553–1557. <http://dx.doi.org/10.1126/science.1212868>.
 20. Abu Kwaik Y, Bumann D. 2013. Microbial quest for food in vivo: 'nutritional virulence' as an emerging paradigm. *Cell Microbiol* 15:882–890. <http://dx.doi.org/10.1111/cmi.12138>.
 21. Schunder E, Gillmaier N, Kutzner E, Herrmann V, Lautner M, Heuner K, Eisenreich W. 2014. Amino acid uptake and metabolism of *Legionella* pneumophila hosted by *Acanthamoeba castellanii*. *J Biol Chem* 289:21040–21054. <http://dx.doi.org/10.1074/jbc.M114.570085>.
 22. Streich FC, Jr, Lima CD. 2014. Structural and functional insights to ubiquitin-like protein conjugation. *Annu Rev Biophys* 43:357–379. <http://dx.doi.org/10.1146/annurev-biophys-051013-022958>.
 23. Ye Y, Rape M. 2009. Building ubiquitin chains: E2 enzymes at work. *Nat Rev Mol Cell Biol* 10:755–764. <http://dx.doi.org/10.1038/nrm2780>.
 24. Ardley HC, Robinson PA. 2005. E3 ubiquitin ligases. *Essays Biochem* 41:15–30. <http://dx.doi.org/10.1042/bse0410015>.
 25. Kerscher O, Felberbaum R, Hochstrasser M. 2006. Modification of proteins by ubiquitin and ubiquitin-like proteins. *Annu Rev Cell Dev Biol* 22:159–180. <http://dx.doi.org/10.1146/annurev.cellbio.22.010605.093503>.
 26. Pickart CM. 2001. Mechanisms underlying ubiquitination. *Annu Rev Biochem* 70:503–533. <http://dx.doi.org/10.1146/annurev.biochem.70.1.503>.
 27. Mukhopadhyay D, Riezman H. 2007. Proteasome-independent functions of ubiquitin in endocytosis and signaling. *Science* 315:201–205. <http://dx.doi.org/10.1126/science.1127085>.
 28. Thrower JS, Hoffman L, Rechsteiner M, Pickart CM. 2000. Recognition of the polyubiquitin proteolytic signal. *EMBO J* 19:94–102. <http://dx.doi.org/10.1093/emboj/19.1.94>.
 29. Chastagner P, Israel A, Brou C. 2006. Itch/AIP4 mediates Deltex degradation through the formation of K29-linked polyubiquitin chains. *EMBO Rep* 7:1147–1153. <http://dx.doi.org/10.1038/sj.embor.7400822>.
 30. Wickliffe K, Williamson A, Jin L, Rape M. 2009. The multiple layers of ubiquitin-dependent cell cycle control. *Chem Rev* 109:1537–1548. <http://dx.doi.org/10.1021/cr800414e>.
 31. Kulathu Y, Komander D. 2012. Atypical ubiquitylation—the unexplored world of polyubiquitin beyond Lys48 and Lys63 linkages. *Nat Rev Mol Cell Biol* 13:508–523. <http://dx.doi.org/10.1038/nrm3394>.
 32. Iwai K, Tokunaga F. 2009. Linear polyubiquitination: a new regulator of NF- κ B activation. *EMBO Rep* 10:706–713. <http://dx.doi.org/10.1038/embo.2009.144>.
 33. Platta HW, Abrahamsen H, Thoresen SB, Stenmark H. 2012. Nedd4-dependent lysine-11-linked polyubiquitination of the tumour suppressor Beclin 1. *Biochem J* 441:399–406. <http://dx.doi.org/10.1042/BJ20111424>.
 34. Jin L, Williamson A, Banerjee S, Philipp I, Rape M. 2008. Mechanism of ubiquitin-chain formation by the human anaphase-promoting complex. *Cell* 133:653–665. <http://dx.doi.org/10.1016/j.cell.2008.04.012>.
 35. Williamson A, Wickliffe KE, Mellone BG, Song L, Karpen GH, Rape M. 2009. Identification of a physiological E2 module for the human anaphase-promoting complex. *Proc Natl Acad Sci U S A* 106:18213–18218. <http://dx.doi.org/10.1073/pnas.0907887106>.
 36. Wickliffe KE, Williamson A, Meyer HJ, Kelly A, Rape M. 2011. K11-linked ubiquitin chains as novel regulators of cell division. *Trends Cell Biol* 21:656–663. <http://dx.doi.org/10.1016/j.tcb.2011.08.008>.
 37. Matsumoto ML, Wickliffe KE, Dong KC, Yu C, Bosanac I, Bustos D, Phu L, Kirkpatrick DS, Hymowitz SG, Rape M, Kelley RF, Dixit VM. 2010. K11-linked polyubiquitination in cell cycle control revealed by a K11 linkage-specific antibody. *Mol Cell* 39:477–484. <http://dx.doi.org/10.1016/j.molcel.2010.07.001>.
 38. Goto E, Yamanaka Y, Ishikawa A, Aoki-Kawasumi M, Mito-Yoshida M, Ohmura-Hoshino M, Matsuki Y, Kajikawa M, Hirano H, Ishido S. 2010. Contribution of lysine 11-linked ubiquitination to MIR2-mediated major histocompatibility complex class I internalization. *J Biol Chem* 285:35311–35319. <http://dx.doi.org/10.1074/jbc.M110.112763>.
 39. Ashida H, Kim M, Sasakawa C. 2014. Exploitation of the host ubiquitin system by human bacterial pathogens. *Nat Rev Microbiol* 12:399–413. <http://dx.doi.org/10.1038/nrmicro3259>.
 40. Zhang Y, Higashide WM, McCormick BA, Chen J, Zhou D. 2006. The inflammation-associated *Salmonella* SopA is a HECT-like E3 ubiquitin ligase. *Mol Microbiol* 62:786–793. <http://dx.doi.org/10.1111/j.1365-2958.2006.05407.x>.
 41. Zhang Y, Higashide W, Dai S, Sherman DM, Zhou D. 2005. Recognition and ubiquitination of *Salmonella* type III effector SopA by a ubiquitin E3 ligase, HsRMA1. *J Biol Chem* 280:38682–38688. <http://dx.doi.org/10.1074/jbc.M506309200>.
 42. Patel JC, Hueffer K, Lam TT, Galan JE. 2009. Diversification of a *Salmonella* virulence protein function by ubiquitin-dependent differential localization. *Cell* 137:283–294. <http://dx.doi.org/10.1016/j.cell.2009.01.056>.
 43. Ruan HH, Li Y, Zhang XX, Liu Q, Ren H, Zhang KS, Zhao H. 2014. Identification of TRAF6 as a ubiquitin ligase engaged in the ubiquitination of SopB, a virulence effector protein secreted by *Salmonella* Typhimurium. *Biochem Biophys Res Commun* 447:172–177. <http://dx.doi.org/10.1016/j.bbrc.2014.03.126>.

44. Kubori T, Galan JE. 2003. Temporal regulation of Salmonella virulence effector function by proteasome-dependent protein degradation. *Cell* 115:333–342. [http://dx.doi.org/10.1016/S0092-8674\(03\)00849-3](http://dx.doi.org/10.1016/S0092-8674(03)00849-3).
45. Kubori T, Hyakutake A, Nagai H. 2008. Legionella translocates an E3 ubiquitin ligase that has multiple U-boxes with distinct functions. *Mol Microbiol* 67:1307–1319. <http://dx.doi.org/10.1111/j.1365-2958.2008.06124.x>.
46. Kubori T, Shinzawa N, Kanuka H, Nagai H. 2010. Legionella metaeffector exploits host proteasome to temporally regulate cognate effector. *PLoS Pathog* 6:e1001216. <http://dx.doi.org/10.1371/journal.ppat.1001216>.
47. Stirling FR, Czucka A, Kelly SM, Oxley D, Evans TJ. 2006. Eukaryotic localization, activation and ubiquitinylation of a bacterial type III secreted toxin. *Cell Microbiol* 8:1294–1309. <http://dx.doi.org/10.1111/j.1462-5822.2006.00710.x>.
48. Anderson DM, Feix JB, Monroe AL, Peterson FC, Volkman BF, Haas AL, Frank DW. 2013. Identification of the major ubiquitin-binding domain of the *Pseudomonas aeruginosa* ExoU A2 phospholipase. *J Biol Chem* 288:26741–26752. <http://dx.doi.org/10.1074/jbc.M113.478529>.
49. Higgs R, Ni Gabhann J, Ben Larbi N, Breen EP, Fitzgerald KA, Jefferies CA. 2008. The E3 ubiquitin ligase Ro52 negatively regulates IFN- β production post-pathogen recognition by polyubiquitin-mediated degradation of IRF3. *J Immunol* 181:1780–1786. <http://dx.doi.org/10.4049/jimmunol.181.3.1780>.
50. Higgs R, Lazzari E, Wynne C, Ni Gabhann J, Espinosa A, Wahren-Herlenius M, Jefferies CA. 2010. Self protection from anti-viral responses—Ro52 promotes degradation of the transcription factor IRF7 downstream of the viral Toll-like receptors. *PLoS One* 5:e11776. <http://dx.doi.org/10.1371/journal.pone.0011776>.
51. Young JA, Sermwittayawong D, Kim HJ, Nandu S, An N, Erdjument-Bromage H, Tempst P, Coscoy L, Winoto A. 2011. Fas-associated death domain (FADD) and the E3 ubiquitin-protein ligase TRIM21 interact to negatively regulate virus-induced interferon production. *J Biol Chem* 286:6521–6531. <http://dx.doi.org/10.1074/jbc.M110.172288>.
52. James LC. 2014. Intracellular antibody immunity and the cytosolic Fc receptor TRIM21. *Curr Top Microbiol Immunol* 382:51–66. http://dx.doi.org/10.1007/978-3-319-07911-0_3.
53. Rhodes DA, Ihrke G, Reinicke AT, Malcherek G, Towey M, Isenberg DA, Trowsdale J. 2002. The 52 000 MW Ro/SS-A autoantigen in Sjogren's syndrome/systemic lupus erythematosus (Ro52) is an interferon- γ inducible tripartite motif protein associated with membrane proximal structures. *Immunology* 106:246–256. <http://dx.doi.org/10.1046/j.1365-2567.2002.01417.x>.
54. Sabile A, Meyer AM, Wirbelauer C, Hess D, Kogel U, Scheffner M, Krek W. 2006. Regulation of p27 degradation and S-phase progression by Ro52 RING finger protein. *Mol Cell Biol* 26:5994–6004. <http://dx.doi.org/10.1128/MCB.01630-05>.
55. Wada K, Niida M, Tanaka M, Kamitani T. 2009. Ro52-mediated monoubiquitination of IKK β down-regulates NF- κ B signalling. *J Biochem* 146:821–832. <http://dx.doi.org/10.1093/jb/mvp127>.
56. Kong HJ, Anderson DE, Lee CH, Jang MK, Tamura T, Taylor P, Cho HK, Cheong J, Xiong H, Morse HC, III, Ozato K. 2007. Cutting edge: autoantigen Ro52 is an interferon inducible E3 ligase that ubiquitinates IRF-8 and enhances cytokine expression in macrophages. *J Immunol* 179:26–30. <http://dx.doi.org/10.4049/jimmunol.179.1.26>.
57. McEwan WA, Tam JC, Watkinson RE, Bidgood SR, Mallery DL, James LC. 2013. Intracellular antibody-bound pathogens stimulate immune signaling via the Fc receptor TRIM21. *Nat Immunol* 14:327–336. <http://dx.doi.org/10.1038/ni.2548>.
58. Habyarimana F, Price CT, Santic M, Al-Khodori S, Kwai YA. 2010. Molecular characterization of the Dot/Icm-translocated AnkH and AnkJ eukaryotic-like effectors of *Legionella pneumophila*. *Infect Immun* 78:1123–1134. <http://dx.doi.org/10.1128/IAI.00913-09>.
59. Huttlin EL, Jedrychowski MP, Elias JE, Goswami T, Rad R, Beausoleil SA, Villen J, Haas W, Sowa ME, Gygi SP. 2010. A tissue-specific atlas of mouse protein phosphorylation and expression. *Cell* 143:1174–1189. <http://dx.doi.org/10.1016/j.cell.2010.12.001>.
60. Eng JK, McCormack AL, Yates JR. 1994. An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database. *J Am Soc Mass Spectrom* 5:976–989. [http://dx.doi.org/10.1016/1044-0305\(94\)80016-2](http://dx.doi.org/10.1016/1044-0305(94)80016-2).
61. Elias JE, Gygi SP. 2007. Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. *Nat Methods* 4:207–214. <http://dx.doi.org/10.1038/nmeth1019>.
62. Beausoleil SA, Villen J, Gerber SA, Rush J, Gygi SP. 2006. A probability-based approach for high-throughput protein phosphorylation analysis and site localization. *Nat Biotechnol* 24:1285–1292. <http://dx.doi.org/10.1038/nbt1240>.
63. Kim W, Bennett EJ, Huttlin EL, Guo A, Li J, Possemato A, Sowa ME, Rad R, Rush J, Comb MJ, Harper JW, Gygi SP. 2011. Systematic and quantitative assessment of the ubiquitin-modified proteome. *Mol Cell* 44:325–340. <http://dx.doi.org/10.1016/j.molcel.2011.08.025>.
64. Kong SK, Chock PB. 1992. Protein ubiquitination is regulated by phosphorylation. An in vitro study. *J Biol Chem* 267:14189–14192.
65. Hou D, Cenciarelli C, Jensen JP, Nguyen HB, Weissman AM. 1994. Activation-dependent ubiquitination of a T cell antigen receptor subunit on multiple intracellular lysines. *J Biol Chem* 269:14244–14247.
66. Dynek JN, Goncharov T, Dueber EC, Fedorova AV, Izrael-Tomasevic A, Phu L, Helgason E, Fairbrother WJ, Deshayes K, Kirkpatrick DS, Vucic D. 2010. c-IAP1 and UbcH5 promote K11-linked polyubiquitination of RIP1 in TNF signalling. *EMBO J* 29:4198–4209. <http://dx.doi.org/10.1038/emboj.2010.300>.
67. Galan JM, Peter M. 1999. Ubiquitin-dependent degradation of multiple F-box proteins by an autocatalytic mechanism. *Proc Natl Acad Sci U S A* 96:9124–9129. <http://dx.doi.org/10.1073/pnas.96.16.9124>.
68. Zhou P, Howley PM. 1998. Ubiquitination and degradation of the substrate recognition subunits of SCF ubiquitin-protein ligases. *Mol Cell* 2:571–580. [http://dx.doi.org/10.1016/S1097-2765\(00\)80156-2](http://dx.doi.org/10.1016/S1097-2765(00)80156-2).
69. Vaysburd M, Watkinson RE, Cooper H, Reed M, O'Connell K, Smith J, Cruickshanks J, James LC. 2013. Intracellular antibody receptor TRIM21 prevents fatal viral infection. *Proc Natl Acad Sci U S A* 110:12397–12401. <http://dx.doi.org/10.1073/pnas.1301918110>.
70. Hauler F, Mallery DL, McEwan WA, Bidgood SR, James LC. 2012. AAA ATPase p97/VCP is essential for TRIM21-mediated virus neutralization. *Proc Natl Acad Sci U S A* 109:19733–19738. <http://dx.doi.org/10.1073/pnas.1210659109>.